The US FDA has approved Invanz (ertapenem), a once-daily injectable antibiotic, for the treatment of moderate to severe complicated foot infection due to indicated pathogens in diabetic patients ...

FDA Approves New Indication for INVANZ (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.

Fresenius Kabi is introducing ertapenem for injection in a 1 gram vial presentation. The new product is the generic of Merck’s Invanz. Ertapenem for injection is indicated in adult patients and ...

INVANZ ® is a registered trademark of Merck Sharp & Dohme Corp. Cautionary Note Regarding Forward-Looking StatementsCertain information in this press release ...

(RTTNews) - Dr. Reddy's Laboratories (RDY) Wednesday announced the launch of Ertapenem for Injection 1 g/vial, a generic version of Invanz, in the U.S. market. Dr. Reddy's Ertapenem for Injection, 1 g ...

Review the side-effects of Ertapenem as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Dr Reddy's Laboratories Ltd on Wednesday announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of Invanz approved by the US Food and Drug Administration. ...

Hyderabad, May 12 () Dr Reddy's Laboratories Ltd on Wednesday announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of Invanz approved by the US Food and ...

The Invanz brand and generic had a market value of $205 million for the 12 months ended March 2021, according to IQVIA. Dr. Reddy’s is introducing ertapenem for injection, 1 g/vial. The product is the ...